The best way to use asparaginase in childhood acute lymphatic leukaemia – still to be defined?
Authors:
Open Access
- 25 February 2004
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 125 (2) , 117-127
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALLLeukemia, 2003
- Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase*Medical and Pediatric Oncology, 2002
- Drug Monitoring of PEG-Asparaginase Treatment in Childhood Acute Lymphoblastic Leukemia and Non-Hodgkin's LymphomaLeukemia & Lymphoma, 2002
- Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countriesBritish Journal of Clinical Pharmacology, 2001
- Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01Blood, 2001
- Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980–1997Leukemia, 2000
- Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparationsEuropean Journal of Cancer, 1996
- L‐Asparaginase: A Review1973
- L-Asparaginase and L-Asparagine MetabolismAnnual Review of Pharmacology, 1970
- A NEW L-ASPARAGINASE WITH ANTITUMOUR ACTIVITYThe Lancet, 1968